168 related articles for article (PubMed ID: 37095262)
21. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
[TBL] [Abstract][Full Text] [Related]
22. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
23. Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
Byrd JB; Chertow GM; Bhalla V
N Engl J Med; 2019 Apr; 380(17):1589-1591. PubMed ID: 30865819
[No Abstract] [Full Text] [Related]
24. Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study.
Ah YM; Lee JY; Choi YJ; Kong J; Kim B; Choi KH; Han N; Yu YM; Oh JM; Shin WG; Lee HY
Clin Exp Hypertens; 2016; 38(3):325-30. PubMed ID: 27028796
[TBL] [Abstract][Full Text] [Related]
25. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
Oparil S
Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
[TBL] [Abstract][Full Text] [Related]
26. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
[TBL] [Abstract][Full Text] [Related]
27. Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Yoo YG; Lim MJ; Kim JS; Jeong HE; Ko H; Shin JY
Medicine (Baltimore); 2023 Nov; 102(46):e36098. PubMed ID: 37986329
[TBL] [Abstract][Full Text] [Related]
28. Modifying prescribing behaviour of angiotensin receptor blockers by selectively rescinding managerial prior authorization requirements for losartan.
Kahan NR; Chinitz DP; Blackman S; Waitman DA; Vardy DA
Br J Clin Pharmacol; 2011 Dec; 72(6):997-1001. PubMed ID: 21689138
[TBL] [Abstract][Full Text] [Related]
29. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin Receptor Blocker-Related Sprue-like Enteropathy: Review of Food and Drug Administration Adverse Event Reporting System.
Meader R; Papasotiriou S; Ahdi H; Dang H; Ehrenpreis ED
Ann Pharmacother; 2024 May; 58(5):494-500. PubMed ID: 37559251
[TBL] [Abstract][Full Text] [Related]
31. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
[TBL] [Abstract][Full Text] [Related]
32. Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Monteiro MA; de Lima PC; Novotny TS; Santana DS; Lima MED; Dantas ASCL; Ferreira LODS; de Souza MN; Maranho RLDN; Ochs SM
J Pharm Sci; 2023 May; 112(5):1305-1314. PubMed ID: 36657719
[TBL] [Abstract][Full Text] [Related]
33. Development of a sensitive LC-APCI-MS/MS method for simultaneous determination of eleven nitrosamines in valsartan and irbesartan with a simple extraction approach.
Mavis ME; Goksu Gursu G; Ular Cagatay N
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Feb; 1216():123593. PubMed ID: 36669257
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
35. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Desai RJ; Ashton CM; Deswal A; Morgan RO; Mehta HB; Chen H; Aparasu RR; Johnson ML
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):233-40. PubMed ID: 21786364
[TBL] [Abstract][Full Text] [Related]
37. Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.
Saseen JJ; Ghushchyan V; Kaila S; Allen RR; Nair KV
J Clin Hypertens (Greenwich); 2013 Dec; 15(12):888-92. PubMed ID: 24102728
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
Li EC; Heran BS; Wright JM
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
[TBL] [Abstract][Full Text] [Related]
39. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
[TBL] [Abstract][Full Text] [Related]
40. Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes.
Hattori N; Yamada A; Nakatsuji S; Matsuda T; Nishiyama N; Shimatsu A
J Mol Endocrinol; 2022 May; 69(1):259-268. PubMed ID: 35354667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
